Other News

DiNAQOR Appoints Two Seasoned Executives to Leadership Team

Chris Rusconi to serve as Chief Development Officer; Steven Zelenkofske to take role of Chief Strategy Officer as DiNAQOR continues rapid growth SCHLIEREN, Switzerland, Jan. 9, 2023 /PRNewswire/ — DiNAQOR, a genetic medicine platform company, today announced that it has added to its leadership team with the appointments of two veteran biotechnology executives. Chris Rusconi, Ph.D., who brings […]

SoniVie Raises $60m in Round C Financing, and Appoints New Board Members

The funds, provided by new investors and current shareholder, will be used to support the Company clinical and regulatory path towards pre-market approval of its TIVUS™ technology for the treatment of hypertension TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire/ — SoniVie Ltd. (“SoniVie” or the “Company”), a medical device company developing a proprietary solution […]

ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. “Bill” Burke as Chief Financial Officer

DENVER, Jan. 9, 2023 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) (the “Company”) today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited) […]

Canon Medical Systems USA Inc. Announces a Strategic Partnership with ScImage

Tustin, California, Jan. 09, 2023 (GLOBE NEWSWIRE) — Canon Medical Systems USA Inc., a commercial subsidiary of Canon Medical Systems Corporation, a global leader in innovative diagnostic imaging technology, today announces the completion of a strategic partnership agreement with ScImage, Inc. Sclmage provides Cloud-native enterprise image management, PACS and image […]

Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results

– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive milestone payments from partners upon regulatory approvals – – Fourth quarter 2022 U.S. net product revenue estimated between $14.4 to […]

New Study Evaluates the Performance of Masimo SpHb® Noninvasive Spot-Check Hemoglobin in the Emergency Department

Masimo SpHb on the Handheld Masimo Rad-67® Demonstrated “Acceptable Accuracy and Excellent Correlation” with Laboratory Hemoglobin NEUCHATEL, Switzerland–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) today announced the results of a prospective study published in the American Journal of Emergency Medicine in which Dr. Zohair Ahmed Ali Al Aseri and colleagues at King Saud University Medical City and […]

Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction

Phase 2 trials underway with ninerafaxstat in three cardiovascular indications; multiple data read-outs expected in 2023 BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced the enrollment of the first patient in Part 2 […]

Nuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results

MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full […]

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones

Phase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301 Anticipated in Second Half 2023 TN-401 IND Submission Planned in Second Half 2023 Cash Runway Extended into First Half 2025 SOUTH SAN […]